News | May 18, 2026
Glenmark Pharma introduces Vancomycin Injection in U.S. market
The product is bioequivalent and therapeutically equivalent to the reference listed drug by Fresenius Kabi USA, LLC.
The product is bioequivalent and therapeutically equivalent to the reference listed drug by Fresenius Kabi USA, LLC.
The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
Final approval for progesterone vaginal inserts expands Glenmark’s women’s healthcare portfolio in the US, targeting a market of over $59 million
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
Dilip Shanghvi to continue as the Executive Chairman of the Board
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
Granules India has reported total income of Rs. 1181.92 crores during the period ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated
